CTI BioPharma, Baxter Announce PROs From Pacritinib Phase 3 In Myelofibrosis

(RTTNews) - CTI BioPharma Corp. (CTIC) and Baxter International Inc.'s (BAX) BioScience business announced Wednesday that Patient Reported Outcomes or PROs data from the Phase 3 PERSIST-1 trial, evaluating pacritinib in patients with myelofibrosis.

Pacritinib is an investigational oral multikinase inhibitor with specificity for JAK2 and FLT3. Myelofibrosis is associated with significantly reduced quality of life and shortened survival. As the disease progresses, the body slows production of important blood cells and within one year of diagnosis the incidence of disease-related thrombocytopenia, severe anemia, and red blood cell transfusion requirements increase significantly.

The company said the PROs data will be highlighted in a late-breaking oral presentation at the upcoming 20th Congress of the European Hematology Association or EHA, June 11-14, Vienna.

These data were also selected for inclusion in the official EHA Press Briefing on Friday, June 12, 2015 at 08:30 CEST.